The above findings suggest that monensin may exert its potent proliferation suppression effect through the inhibition of multiple growth factor-induced signal pathways, especially EGFR, which is found overexpressed in the clinical samples of pancreatic cancer. The gene discussed is EGFR; the disease is familial pancreatic carcinoma.